Truvada Sales Drive Gilead Sciences' 58% Increase in Third-Quarter Profits
October 20, 2005
Foster City, Calif.-based Gilead Sciences on Tuesday announced that its third-quarter profits for 2005 rose to $179.2 million, 58% higher than during the same time period last year, primarily because of a 59% increase in sales of its antiretroviral drugs, Reuters reports. Gilead recorded $162.4 million in second-quarter sales for its combination antiretroviral drug Truvada, which combines its antiretrovirals Viread and Emtriva (Beasley, Reuters, 10/18). Third-quarter sales of Truvada -- which was approved by FDA in August 2004 -- increased 32% over the second quarter of 2005 (Kaiser Daily HIV/AIDS Report, 7/21). Sales of Viread in the third quarter of 2005 decreased 2% to $189.4 million from the third quarter of 2004, and Emtriva sales decreased 26% to $11.7 million, with many patients switching to Truvada (Gilead release, 10/18). According to Gilead, about 60% of newly diagnosed AIDS patients in the U.S. are being treated with Truvada (Reuters, 10/18).
Trimeris Says Third-Quarter Sales of Fuzeon Down From Second Quarter
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.